SLC5A2 and diabetes mellitus: Diabetes can lead to increased risks for cardiovascular disease including heart failure, and glycemic control drugs including sodium-glucose transporter 2 (SGLT2) inhibitors have substantially improved the management of patients with diabetes and reduced patients’ cardiovascular complications [39].